This is the authors' abstract. We don't add key points for this paper.
Oncolytic viruses (OVs) have matured from a provocative concept into an established therapeutic modality capable of both direct tumor cytolysis and immune activation.1 Among viral backbones, herpes simplex virus type I (HSV-I) is a favored platform for oncolytic virus engineering, given its large genome, broad cellular tropism, and clinical precedence with talimogene laherparepvec (T-VEC), the first oncolytic virus approved by the Food and Drug Administration (FDA) to treat metastatic melanoma.2 These advances have reframed OVs not merely as lytic agents but as vectors for precise immunological engineering.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dhital et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: